The PML-RARα transcript in long-term follow-up of acute promyelocytic leukemia patients

Haematologica

Volumn 86, Issue 6, 2001, Pages 577-585

  Gameiro, P ^a   Vieira, S ^a   Carrara, P ^a   Silva, A L ^a   Diamond, J ^a   De Sousa, A B ^a   Mehta, A B ^a   Prentice, H G ^a   Guimaraes J E ^a   Hoffbrand, A V ^a   Foroni, L ^a   Parreira, A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

APL; Minimal residual disease; RAR

Indexed keywords

HYBRID PROTEIN; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN RAR ALPHA; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0034962192     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor α locus
2. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17
3. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoid acid receptor α gene to a novel transcribed locus
4. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor
5. Molecular monitoring of the myl/retinoic acid receptor-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction
6. A PML/retinoic acid receptor α fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia
7. The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
8. Rearrangements and aberrant expression of the retinoic acid receptor α in acute promyelocytic leukemias
9. Genomic variability and alternative splicing generate multiple PML/RARα transcripts that encode aberrant PML/RARα isoforms in acute promyelocytic leukaemia
10. The t(15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene: Targets for the detection of minimal residual disease by the polymerase chain reaction
11. Acute promyelocytic leukemia: Clinical relevance of two major PML-RARα isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse
12. Prognostic significance of the RT-PCR assay of PML-RARα transcripts in acute promyelocytic leukemia
13. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia
14. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia
15. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA
16. Relapse of acute promyelocytic leukemia follows serial negative RT-PCR assays: A cautionary tale
17. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial
18. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation of PML-RARα and RARα-PML assessment in patients who ultimately relapse
19. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial
20. Proposals for the classification of the acute leukaemias
21. Single step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction
22. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
23. Regression models and life-tables
24. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia
25. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
26. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission
27. Molecular analysis of PML/RARα fusion mRNA detected by reverse transcription-polymerase chain reaction assay in long-term disease-free acute promyelocytic leukaemia patients
28. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response
29. Quantification of PML-RARα transcripts in acute promyelocytic leukaemia: Explanation for lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by α interferon
30. Predicting relapse in APL by quantitating PML-RARα transcripts with a highly sensitive competitive RT-PCR
31. High BCR-ABL transcript levels precede haematological relapse in Philadelphia positive acute leukemia
32. The significance of BCR-ABL "molecular relapse" in CML patients 18 months or more post-transplant
33. Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial
34. Quantification of minimal residual disease in acute promyelocytic patients with t(15;17) translocation using real-time RT-PCR
35. Short-term intensive consolidation therapy after all-trans retinoic acid in acute promyelocytic leukemia
36. The APL-associated fusion proteins
37. Diagnosis, front line treatment and molecular monitoring of acute promyelocytic leukaemia
38. Development and overcoming of ATRA resistance in acute promyelocytic leukemia
39. Arsenicals and inhibitors of histone deacetylase as anticancer therapy